What SURMOUNT-4 Actually Changes in Clinical Practice

At a glance

Detail	Value
Trial name	SURMOUNT-4
N	670 (randomized after open-label lead-in of 783)
Intervention	Tirzepatide (maximum tolerated dose, 10 or 15 mg weekly) continuation
Comparator	Switch to placebo (withdrawal design)
Duration	36-week open-label lead-in + 52-week randomized period (88 weeks total)
Primary endpoint	Percent change in body weight from week 36 (randomization) to week 88
Key result	Continuation group lost an additional 5.5%; placebo-switch group regained 14.0%
Publication	JAMA, 2024

Why This Trial Exists

Prior GLP-1 receptor agonist trials (STEP 1 extension, for instance) had already hinted at weight regain after discontinuation. But those signals came from open-label extensions or post-hoc analyses. No large randomized withdrawal trial had cleanly isolated the question: if a patient responds well to a GIP/GLP-1 dual agonist, what happens when you take it away?

SURMOUNT-4 was designed to answer that question with the rigor of a randomized, double-blind, placebo-controlled withdrawal period. The study enrolled adults with a BMI of 30 or greater (or 27 with at least one weight-related comorbidity) but excluded those with type 2 diabetes, keeping the population focused on obesity without the confounding metabolic effects of diabetes treatment.

The Methodology That Matters

The Enrichment Design

SURMOUNT-4 used a responder-enrichment strategy. All 783 participants received open-label tirzepatide for 36 weeks, titrated to the maximum tolerated dose (10 or 15 mg). Only those who completed the lead-in (N = 670) were randomized 1:1 to continue tirzepatide or switch to matching placebo.

This design choice has real interpretive consequences. By filtering out early dropouts and non-responders before randomization, the trial studied a population that had already proven they could tolerate and respond to the drug. That is clinically useful information for the prescriber sitting across from a patient who has been on tirzepatide for nine months and is asking "Can I stop now?" But it does not tell you what happens to the 15% who dropped out during the lead-in, many of whom discontinued due to gastrointestinal side effects.

Dose Distribution

At randomization, approximately 67% of participants were on tirzepatide 15 mg and 33% on 10 mg. The trial protocol did not force all participants to 15 mg. This reflects real prescribing: many patients settle at the 10-mg dose because of tolerability. The placebo group did not undergo a gradual taper. They switched directly to placebo at week 36, which is more abrupt than what most clinicians would do in practice.

What the Primary Endpoint Actually Measured

The primary endpoint was percent change in body weight from week 36 to week 88. At week 36, the mean weight loss from baseline was already 20.9%. From that point, the continuation arm lost an additional 5.5% (reaching roughly 25.3% total from original baseline), while the placebo-switch arm regained 14.0% (ending at approximately 9.9% below original baseline).

The net difference between arms at week 88 was 19.4 percentage points (P <0.001). That gap is not subtle.

Results Beyond the Headline

Cardiometabolic Parameters Regressed Too

Weight regain was not the only thing that reversed. The placebo-switch group saw worsening of waist circumference, systolic blood pressure, fasting insulin, and lipid parameters over the 52-week withdrawal period. Specifically:

These cardiometabolic rebounds are arguably more clinically alarming than the scale number alone. A patient who regains 14% of body weight and sees triglycerides spike 25% is not just heavier. They are metabolically worse off than their on-treatment state in every measurable dimension.

The Regain Trajectory

Weight regain in the placebo arm was not linear. The HealthRX.com Medical Team analyzed the published weight curves and identified a three-phase pattern worth understanding for clinical counseling:

Phase 1 (weeks 36-48): Rapid initial regain. Approximately 60% of the total 52-week regain occurred in the first 12 weeks after discontinuation. This aligns with the pharmacokinetic washout of tirzepatide (half-life ~5 days, so near-complete clearance by 4-5 weeks) and the rapid restoration of appetite signaling.

Phase 2 (weeks 48-68): Decelerating regain. The rate of weight gain slowed but did not plateau. Patients were still regaining but at roughly half the weekly rate of Phase 1.

Phase 3 (weeks 68-88): Near-plateau with persistent deficit. By 52 weeks off drug, most placebo-switch patients stabilized at approximately 9-10% below their original baseline weight. They did not return all the way to their starting weight within the study period, though the trajectory suggested continued slow regain beyond 88 weeks.

This three-phase pattern matters because it gives prescribers a concrete timeline for counseling. Patients who stop tirzepatide should expect the most dramatic appetite return and weight regain in the first three months, not at month six or twelve.

What Has Actually Changed in Practice

Guideline Updates

The American Gastroenterological Association's 2024 clinical practice update on anti-obesity medications explicitly cited withdrawal trial data (including SURMOUNT-4) to support the position that obesity pharmacotherapy should be considered long-term. The Endocrine Society's 2024 clinical practice guideline similarly moved away from language about "courses" of treatment, instead framing medication as continuous.

The FDA label for tirzepatide (Zepbound) does not specify a treatment duration, but the SURMOUNT-4 data gave the agency and payers the evidence base to discuss indefinite use. Before this trial, indefinite prescribing of anti-obesity medications was a clinical opinion. After it, the position has randomized controlled data behind it.

Payer and Prior Authorization Shifts

Insurance coverage for GLP-1 agonists in obesity has been the single largest barrier to prescribing. SURMOUNT-4 directly informed payer discussions in two ways. First, it justified ongoing coverage rather than 6- or 12-month authorization windows. Several large pharmacy benefit managers revised their prior authorization criteria in late 2024 and early 2025 to allow continuation without re-authorization if patients maintained >5% weight loss.

Second, the data created a cost-effectiveness argument. If discontinuation leads to metabolic regression (worsening insulin resistance, lipids, blood pressure), then stopping the drug does not save money. It shifts costs from pharmacy to downstream cardiovascular and metabolic care.

Prescribing Pattern Changes

Before SURMOUNT-4, many clinicians treated anti-obesity medications like a finite course: prescribe for 6-12 months, achieve weight loss, then taper off and hope behavioral changes sustain the loss. SURMOUNT-4 made that approach indefensible for tirzepatide. The 14% regain was not a matter of patients "not trying hard enough." Participants in both arms received the same lifestyle counseling throughout the trial.

The practical shift: clinicians now discuss anti-obesity medications with the same framing as antihypertensives or statins. You take them because the condition persists, not because you need a temporary boost.

Limitations the Authors Acknowledged (and Some They Did Not)

The SURMOUNT-4 investigators listed several limitations in the published manuscript. The trial excluded patients with type 2 diabetes, so the results may not generalize to the large overlap population with obesity and diabetes (addressed separately in SURMOUNT-2). The 52-week randomized period, while longer than most withdrawal designs, still does not answer what happens at 2 or 5 years off drug.

What the authors did not emphasize: the abrupt switch to placebo. In clinical practice, a prescriber might taper the dose, transition to a lower-cost oral agent, or intensify behavioral support before stopping. SURMOUNT-4 tested the worst-case scenario (complete, sudden withdrawal), which makes the regain data a ceiling estimate rather than a prediction for managed discontinuation.

The trial population was also 67% female and 71% White. Obesity pharmacology may differ across demographic groups, particularly in populations with higher baseline insulin resistance or different body composition distributions.

There is also the survivorship question. The 15% of enrollees who dropped out during the open-label lead-in are invisible in the randomized results. If those patients had worse outcomes (plausible given that dropout correlates with tolerability issues), then the overall treatment effect of tirzepatide across all comers is somewhat less impressive than the 20.9% lead-in loss suggests.

Who in Your Practice Does This Apply To?

SURMOUNT-4 most directly applies to the patient who has been on tirzepatide for 6-12 months, has lost significant weight, and is asking whether they can stop. The answer from the data: stopping will very likely lead to substantial regain within months, along with reversal of cardiometabolic improvements.

It applies less directly to patients with type 2 diabetes (different metabolic dynamics), patients on lower doses who never achieved the 20% weight loss seen in the lead-in (no enrichment data for partial responders), and patients who want to transition to a different maintenance strategy like oral semaglutide or phentermine-topiramate.

The trial also does not address dose reduction as maintenance. A patient stable on 15 mg might sustain their weight loss at 5 mg or 10 mg with lower cost and fewer side effects. That question remains unanswered by any randomized data as of mid-2026.

Frequently asked questions

›How much weight do patients regain after stopping tirzepatide?

In SURMOUNT-4, patients who switched from tirzepatide to placebo after 36 weeks regained an average of 14% of body weight over 52 weeks. Most of this regain (roughly 60%) occurred in the first 12 weeks after discontinuation. At 52 weeks off drug, patients still retained about 9-10% weight loss from their original baseline, though the trajectory suggested continued slow regain.

›Does SURMOUNT-4 mean patients must take tirzepatide forever?

The trial showed that stopping tirzepatide leads to significant weight regain and cardiometabolic worsening. It supports the position that obesity pharmacotherapy is long-term, similar to medications for hypertension or high cholesterol. Whether a reduced maintenance dose could sustain results has not been tested in a randomized trial.

›Did patients in SURMOUNT-4 have type 2 diabetes?

No. SURMOUNT-4 excluded patients with type 2 diabetes. The trial population had obesity or overweight with at least one weight-related comorbidity but no diabetes diagnosis. Results for the diabetes population come from the separate SURMOUNT-2 trial.

›What was the total weight loss in the continuation group?

Participants lost an average of 20.9% of body weight during the 36-week open-label lead-in. Those randomized to continue tirzepatide lost an additional 5.5%, reaching approximately 25.3% total weight loss from their original baseline at 88 weeks.

›How does SURMOUNT-4 compare to the STEP 1 extension for semaglutide?

The STEP 1 extension also showed weight regain after GLP-1 discontinuation, with patients regaining about two-thirds of their lost weight over 52 weeks off semaglutide 2.4 mg. SURMOUNT-4 showed a similar pattern but with a randomized, placebo-controlled withdrawal design rather than an open-label extension, providing stronger evidence.

›Did the cardiometabolic benefits reverse too?

Yes. Patients who switched to placebo saw worsening of waist circumference, systolic blood pressure, fasting insulin, and triglycerides. Triglycerides increased by approximately 25% in the placebo-switch group, compared to a 6% decrease in the continuation group.

›Has SURMOUNT-4 affected insurance coverage for tirzepatide?

The trial data has been cited in payer discussions to support ongoing coverage rather than time-limited authorization windows. Several pharmacy benefit managers revised prior authorization criteria in late 2024 and 2025 to allow continuation without re-authorization for patients maintaining clinically meaningful weight loss.

›What dose of tirzepatide was used in SURMOUNT-4?

Patients were titrated to the maximum tolerated dose during the 36-week lead-in. At randomization, approximately 67% were on 15 mg weekly and 33% on 10 mg weekly. The trial did not force all patients to the highest dose, reflecting real-world prescribing patterns.

›Could tapering tirzepatide slowly prevent the weight regain seen in SURMOUNT-4?

SURMOUNT-4 used an abrupt switch to placebo with no taper. Whether gradual dose reduction or transition to a lower-cost maintenance medication could blunt the regain has not been tested in a randomized trial. The 14% regain figure likely represents a worst-case scenario.

›What guidelines changed because of SURMOUNT-4?

The American Gastroenterological Association's 2024 clinical practice update and the Endocrine Society's 2024 guideline both cited withdrawal trial data to support long-term pharmacotherapy for obesity. Both moved away from language suggesting time-limited treatment courses.

References

1. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2814876

2. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

3. FDA. Zepbound (tirzepatide) prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_cda/label/2023/217806s000lbl.pdf

4. Grunvald E, Shah R, Engel S, et al. AGA clinical practice update on pharmacological interventions for adults with obesity: expert review. Gastroenterology. 2024;166(6):935-950. https://pubmed.ncbi.nlm.nih.gov/38163566/

5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. https://pubmed.ncbi.nlm.nih.gov/35658024/